Prelude Therapeutics Incorporated
PRLD
$3.36
$0.061.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.72% | 38.88% | 10.10% | -2.08% | 13.13% |
| Total Depreciation and Amortization | -14.52% | 4.94% | -4.20% | 2.11% | 47.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.47% | -49.90% | -22.84% | -2.83% | -41.07% |
| Change in Net Operating Assets | 765.83% | -175.67% | -87.82% | -32.08% | 15.33% |
| Cash from Operations | 211.45% | 29.97% | -13.09% | -7.68% | 12.02% |
| Capital Expenditure | 100.00% | 100.00% | 94.43% | 83.74% | 95.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -372.15% | 271.35% | -56.41% | 97.50% | 150.10% |
| Cash from Investing | -372.80% | 273.53% | -55.89% | 99.18% | 185.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 44.79% | -- | -- |
| Issuance of Common Stock | 20,020.16% | -100.00% | -64.20% | -- | -99.51% |
| Repurchase of Common Stock | 28.57% | 61.54% | 88.89% | 68.75% | -600.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 73,464.71% | 96.18% | -37.29% | -1,042.86% | -100.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,016.12% | 225.62% | -565.14% | 4,859.42% | -85.74% |